PHVS
Pharvaris N.V. NASDAQ Listed Feb 5, 2021$32.80
-1.83%
vs $33.41
Mkt Cap $1.9B
52w Low $16.64
96.4% of range
52w High $33.41
50d MA $29.96
200d MA $26.43
P/E (TTM)
-11.0x
EV/EBITDA
—
P/B
7.2x
Debt/Equity
0.0x
ROE
—
P/FCF
-14.1x
RSI (14)
62.50
ATR (14)
$1.59
Beta
-2.58
50d MA
$29.96
200d MA
$26.43
Avg Volume
347.4K
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
J.H. Oortweg 21 · Leiden 2333 CH · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | — | — | — | 31.25 | +2.5% | +5.4% | -6.8% | -1.0% | -5.2% | +0.5% | — |
| May 12, 2026 | BMO | -0.82 | -0.68 | +17.1% | 29.95 | +0.2% | +4.3% | +5.4% | -6.8% | -1.0% | -5.2% | — |
| Apr 2, 2026 | BMO | -0.71 | -0.85 | -18.3% | 28.56 | +0.7% | -0.7% | -1.9% | -1.0% | -1.8% | -1.6% | — |
| Nov 12, 2025 | BMO | -0.78 | -0.70 | +10.3% | 25.81 | +0.3% | -6.0% | -2.9% | +5.8% | -3.8% | +2.4% | — |
| Aug 12, 2025 | BMO | -0.87 | -0.94 | -8.0% | 21.09 | +2.3% | +1.6% | +7.3% | -3.0% | -0.6% | +5.0% | — |
| May 13, 2025 | BMO | -0.80 | -0.89 | -11.2% | 16.11 | +1.7% | -0.2% | -1.0% | +4.1% | +0.8% | +3.4% | — |
| Mar 31, 2025 | BMO | — | -0.93 | — | 15.70 | -1.3% | -5.5% | +0.8% | -2.2% | -2.3% | -7.5% | — |
| Nov 13, 2024 | BMO | -0.66 | -0.85 | -28.8% | 20.04 | -0.1% | +2.5% | -1.0% | +2.8% | -2.0% | -0.0% | — |
| Aug 14, 2024 | BMO | -0.57 | -0.59 | -3.5% | 16.90 | +0.2% | +13.6% | -2.3% | -0.3% | -4.7% | -0.2% | — |
| May 8, 2024 | BMO | -0.56 | -0.56 | +0.0% | 20.85 | -0.6% | -1.3% | +4.3% | -1.4% | -1.7% | +6.2% | — |
| Apr 3, 2024 | BMO | -0.58 | -0.82 | -41.4% | 22.29 | -3.1% | +0.6% | +0.6% | +0.8% | +1.8% | -3.8% | — |
| Nov 2, 2023 | BMO | -0.67 | -0.63 | +6.0% | 17.18 | +1.7% | +7.6% | -8.2% | +2.4% | -1.0% | -2.6% | — |
| Aug 7, 2023 | BMO | -0.71 | -0.69 | +2.8% | 17.52 | +1.5% | +3.2% | -4.6% | +6.1% | +1.4% | -0.8% | — |
| May 8, 2023 | AMC | -0.81 | -0.72 | +11.1% | 9.26 | -0.6% | -8.2% | +0.0% | -3.4% | -2.6% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | Wedbush | Maintains | Outperform → Outperform | — | $28.37 | $28.50 | +0.5% | -1.9% | -1.0% | -1.8% | -1.6% | +4.7% |
| Apr 6 | RBC Capital | Maintains | Outperform → Outperform | — | $28.56 | $28.75 | +0.7% | -0.7% | -1.9% | -1.0% | -1.8% | -1.6% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.00 | $27.49 | -1.8% | -4.4% | +0.1% | -3.6% | +0.3% | +2.3% |
| Dec 4 | BofA Securities | Maintains | Neutral → Neutral | — | $29.37 | $29.18 | -0.6% | -5.7% | -4.6% | -4.0% | -5.2% | -1.5% |
| Dec 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.37 | $29.18 | -0.6% | -5.7% | -4.6% | -4.0% | -5.2% | -1.5% |
| Dec 4 | Guggenheim | Maintains | Buy → Buy | — | $29.37 | $29.18 | -0.6% | -5.7% | -4.6% | -4.0% | -5.2% | -1.5% |
| Dec 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $29.37 | $29.18 | -0.6% | -5.7% | -4.6% | -4.0% | -5.2% | -1.5% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.12 | $24.13 | +0.0% | +21.8% | -5.7% | -4.6% | -4.0% | -5.2% |
| Nov 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $24.26 | $24.36 | +0.4% | -2.9% | +5.8% | -3.8% | +2.4% | -1.4% |
| Nov 13 | Wedbush | Maintains | Outperform → Outperform | — | $25.81 | $25.88 | +0.3% | -6.0% | -2.9% | +5.8% | -3.8% | +2.4% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.81 | $25.88 | +0.3% | -6.0% | -2.9% | +5.8% | -3.8% | +2.4% |
| Oct 9 | BofA Securities | Upgrade | Underperform → Neutral | — | $22.98 | $23.62 | +2.8% | -0.6% | -3.8% | +0.4% | -5.0% | +3.9% |
| Aug 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.09 | $21.58 | +2.3% | +1.6% | +7.3% | -3.0% | -0.6% | +5.0% |
| Jun 5 | Wedbush | Maintains | Outperform → Outperform | — | $16.62 | $16.61 | -0.1% | -3.4% | +4.5% | +7.4% | +0.5% | -5.9% |
| May 14 | Wedbush | Maintains | Outperform → Outperform | — | $16.11 | $16.38 | +1.7% | -0.2% | -1.0% | +4.1% | +0.8% | +3.4% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.11 | $16.38 | +1.7% | -0.2% | -1.0% | +4.1% | +0.8% | +3.4% |
| Mar 3 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $15.90 | $16.05 | +0.9% | -3.6% | +0.8% | -3.0% | +3.1% | -2.8% |
| Jan 31 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $17.73 | $18.28 | +3.1% | -0.7% | -2.6% | +0.2% | +2.1% | +4.2% |
| Sep 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $19.10 | $19.57 | +2.5% | +0.1% | +3.8% | +7.8% | -2.0% | -2.2% |
| Jul 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.85 | $17.19 | +2.0% | +0.9% | -2.1% | +4.7% | -0.5% | +2.1% |
| May 9 | Wedbush | Maintains | Outperform → Outperform | — | $20.85 | $20.72 | -0.6% | -1.3% | +4.3% | -1.4% | -1.7% | +6.2% |
| Apr 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $19.16 | $19.50 | +1.8% | +8.9% | +2.0% | -0.2% | +7.2% | +2.5% |
| Apr 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $21.90 | $21.75 | -0.7% | -8.0% | +4.2% | +1.0% | -13.1% | +4.0% |
| Apr 11 | Wedbush | Maintains | Outperform → Outperform | — | $22.27 | $23.94 | +7.5% | +0.2% | -1.8% | -8.0% | +4.2% | +1.0% |
| Apr 11 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $22.27 | $23.94 | +7.5% | +0.2% | -1.8% | -8.0% | +4.2% | +1.0% |
| Mar 19 | Wedbush | Maintains | Outperform → Outperform | — | $24.83 | $24.85 | +0.1% | +4.7% | -4.1% | +0.3% | -2.6% | -12.7% |
| Mar 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $39.23 | $38.48 | -1.9% | -1.2% | -0.6% | -12.7% | -14.5% | -5.9% |
| Mar 2 | BofA Securities | Maintains | Neutral → Neutral | — | $39.23 | $38.48 | -1.9% | -1.2% | -0.6% | -12.7% | -14.5% | -5.9% |
| Mar 2 | SVB Leerink | Maintains | Outperform → Outperform | — | $39.23 | $38.48 | -1.9% | -1.2% | -0.6% | -12.7% | -14.5% | -5.9% |
| Mar 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $39.23 | $38.48 | -1.9% | -1.2% | -0.6% | -12.7% | -14.5% | -5.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Modig Berndt | Chief Executive Officer | Sell | 100 | $31.46 | $3K | 135,209 | -1.83% | — |
| Jun 15, 2026 | Modig Berndt | Chief Executive Officer | Sell | 2,191 | $31.05 | $68K | 135,309 | -1.83% | — |
| Jun 4, 2026 | Nijdam Anna | Principal Accounting Officer | Sell | 2,670 | $30.87 | $82K | 46,275 | +0.03% | +2.67% |
| May 22, 2026 | Nijdam Anna | Principal Accounting Officer | Sell | 5,501 | $30.74 | $169K | 48,945 | -1.37% | -0.41% |
| May 21, 2026 | Nassif David W. | CFO / CLO | Sell | 10,000 | $30.31 | $303K | 120,300 | -1.37% | -0.41% |
| May 21, 2026 | Monges Viviane | — | Sell | 9,667 | $30.29 | $293K | 5,500 | -1.37% | -0.41% |
| May 21, 2026 | Nijdam Anna | Principal Accounting Officer | Sell | 1,829 | $30.60 | $56K | 48,945 | -1.37% | -0.41% |
| May 18, 2026 | Modig Berndt | Chief Executive Officer | Sell | 2,292 | $29.22 | $67K | 137,500 | +3.70% | +1.32% |
| May 15, 2026 | Abele Stefan Andreas | Chief Technical Ops Officer | Sell | 8,748 | $29.82 | $261K | 35,194 | +1.73% | -1.37% |
| May 15, 2026 | Souverijns Wim | Chief Commercial Officer | Sell | 10,000 | $29.92 | $299K | 45,111 | +1.73% | -1.37% |
| May 15, 2026 | Glassman Robert | — | Sell | 4,667 | $29.82 | $139K | 10,500 | +1.73% | -1.37% |
| May 15, 2026 | Glassman Robert | — | Sell | 5,333 | $29.83 | $159K | 15,167 | +1.73% | -1.37% |
| May 1, 2026 | Lu Peng | Chief Medical Officer | Sell | 143 | $31.00 | $4K | 66,083 | +0.30% | +4.34% |
| May 1, 2026 | Lu Peng | Chief Medical Officer | Sell | 14,023 | $30.16 | $423K | 66,226 | +0.30% | +4.34% |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus | — | Sell | 670 | $31.03 | $21K | 355,167 | +1.97% | +1.38% |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus | — | Sell | 28,400 | $30.30 | $861K | 355,837 | +1.97% | +1.38% |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | Sell | 19,200 | $30.26 | $581K | 133,969 | +1.97% | +1.38% |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | Sell | 18,000 | $30.26 | $545K | 56,450 | +1.97% | +1.38% |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | Sell | 3,700 | $30.26 | $112K | 56,450 | +1.97% | +1.38% |
| Apr 30, 2026 | Lu Peng | Chief Medical Officer | Sell | 15,000 | $30.24 | $454K | 66,083 | +1.97% | +1.38% |
| Apr 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus | — | Sell | 3,830 | $30.07 | $115K | 384,237 | +1.97% | +1.38% |
| Apr 29, 2026 | Lesage Anne | Chief Early Development | Sell | 3,700 | $30.08 | $111K | 56,450 | +1.97% | +1.38% |
| Apr 29, 2026 | Lu Peng | Chief Medical Officer | Sell | 3,733 | $30.06 | $112K | 62,350 | +1.97% | +1.38% |
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | General Atlantic, L.p. | 8,031,252 | $227M | — | Mar 2026 |
| 2 | Fmr Llc | 6,284,472 | $178M | Reduced | Mar 2026 |
| 3 | Foresite Capital Management Iv, Llc | 4,778,581 | $135M | — | Mar 2026 |
| 4 | Viking Global Investors | 3,653,310 | $103M | — | Mar 2026 |
| 5 | Deerfield Management Company, L.p. | 3,126,042 | $88M | — | Mar 2026 |
| 6 | Point72 Asset Management | 1,007,016 | $28M | Added | Mar 2026 |
| 7 | Soleus Capital Management, L.p. | 702,052 | $20M | — | Mar 2026 |
| 8 | Morgan Stanley | 496,668 | $14M | Added | Dec 2025 |
| 9 | D.e. Shaw & Co | 321,157 | $9M | Added | Mar 2026 |
| 10 | Kalehua Capital Management Llc | 198,772 | $6M | — | Mar 2026 |
| 11 | Millennium Management | 181,946 | $5M | Reduced | Mar 2026 |
| 12 | Citadel Advisors Llc | 168,630 | $5M | Added | Mar 2026 |
| 13 | Jones Hill Capital Lp | 167,014 | $5M | New | Mar 2026 |
| 14 | Schroder Investment Management Group | 158,019 | $4M | — | Mar 2026 |
| 15 | Two Sigma Investments, Lp | 126,076 | $4M | Reduced | Mar 2026 |
| 16 | Alyeska Investment Group, L.p. | 125,000 | $4M | — | Mar 2026 |
| 17 | Adar1 Capital Management, Llc | 105,528 | $3M | New | Mar 2026 |
| 18 | Stempoint Capital Lp | 86,637 | $2M | New | Mar 2026 |
| 19 | Northern Trust Corp | 83,468 | $2M | Added | Mar 2026 |
| 20 | Ubs Group Ag | 71,941 | $2M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 11
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Core MSCI EAFE ETF | 108,453 | $3M | Jan 2026 |
| 2 | ALPS Medical Breakthroughs ETF | 57,094 | $2M | Feb 2026 |
| 3 | iShares MSCI Netherlands ETF | 24,415 | $693K | Feb 2026 |
| 4 | Virtus LifeSci Biotech Clinical Trials ETF | 11,661 | $315K | Jan 2026 |
| 5 | Invesco Nasdaq Biotechnology ETF | 3,591 | $102K | Feb 2026 |
| 6 | iShares MSCI Europe Small-Cap ETF | 2,072 | $56K | Jan 2026 |
| 7 | Victory Science & Technology Fund | 2,001 | $54K | Jan 2026 |
| 8 | First Trust IPOX Europe Equity Opportunities ETF | 406 | $11K | Mar 2026 |
| 9 | Knights of Columbus U.S. ALL CAP INDEX FUND | 286 | $8K | Jan 2026 |
| 10 | Xtrackers MSCI Eurozone Hedged Equity ETF | 176 | $5K | Feb 2026 |
| 11 | Goldman Sachs MSCI World Private Equity Return Tracker ETF | 55 | $2K | Feb 2026 |
Valuation
Market Cap
$1.94B
Enterprise Value
$1.65B
P/E (TTM)
-11.04x
Forward P/E
—
PEG Ratio
-0.40x
P/B
7.15x
P/S
—
P/FCF
-14.14x
EV/EBITDA
—
Shares Out
59.2M
Financials (TTM)
Revenue
$0
Net Income
-$175.7M
EBITDA
-$169.4M
Free Cash Flow
-$137.2M
Op Cash Flow
-$137.1M
EPS Basic
$-2.97
EPS Diluted
$-2.97
EPS Forward
$-3.02
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$301.5M
Total Liab.
$30.2M
Total Equity
$271.3M
Cash
$291.7M
LT Debt
$0
Book Value/Sh
$4.59
Debt/Equity
0.00x
Current Ratio
10.11
Quick Ratio
10.11
Returns & Growth
ROE
—
ROA
—
ROIC
-62.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
-19.8%
Price Returns
2W
-1.8%
1M
-2.7%
3M
+6.2%
6M
+6.3%
12M
+81.7%
Technicals
52W High
$33.41
52W Low
$16.64
50d MA
$29.96
200d MA
$26.43
RSI (14)
62.50
ATR (14)
$1.59
Beta
-2.58
Avg Volume
347K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$43.67
High
$52.00
Low
$38.00
Median
$41.50
Data updated apr 26, 2026 7:38pm
· Source: financialmodelingprep.com